<bill session="117" type="h" number="6972" updated="2023-08-07T16:15:22Z">
  <state datetime="2022-03-08">REFERRED</state>
  <status>
    <introduced datetime="2022-03-08"/>
  </status>
  <introduced datetime="2022-03-08"/>
  <titles>
    <title type="display">Give Kids a Chance Act of 2022</title>
    <title type="short" as="introduced">Give Kids a Chance Act of 2022</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to establish additional authorities of the Food and Drug Administration regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="B001251"/>
  <cosponsors>
    <cosponsor bioguide_id="M001157" joined="2022-03-08"/>
    <cosponsor bioguide_id="M001190" joined="2022-03-24"/>
    <cosponsor bioguide_id="N000191" joined="2022-05-10"/>
    <cosponsor bioguide_id="O000171" joined="2022-03-16"/>
    <cosponsor bioguide_id="W000826" joined="2022-03-18"/>
  </cosponsors>
  <actions>
    <action datetime="2022-03-08">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-03-08" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-03-09">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="5416" relation="unknown"/>
    <bill session="117" type="s" number="4215" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-08-07T16:10:35Z" status="Introduced in House">Give Kids a Chance Act of 2022

This bill authorizes the Food and Drug Administration (FDA) to take various actions regarding pediatric cancer treatments, such as requiring pediatric cancer trials involving a combination of drugs when an applicant seeks market approval for a new drug (or biological product).</summary>
</bill>
